Blinatumomab, a well-characterized BiTE targeting both CD19 and CD3 was approved by the FDA for the treatment of a rare type of acute lymphoblastic leukemia (ALL) in 2017 [74]. Here, CD19 is linked to acute lymphoblastic leukemia.